#ICYMI It’s Pulmonary Fibrosis Awareness Month (#PFMonth) and Endeavor Biomedicines’ CEO John Hood, PhD, shares his POV on the urgency of delivering more effective treatments for people with #IPF. Read more here: bit.ly/47sThG1

Idiopathic pulmonary fibrosis (#IPF) is a chronic #lungdisease that causes scarring in the lungs. This impactful #PFAM video from Action for Pulmonary Fibrosis demonstrates how scarring can make it hard to breathe. #PFMonth24 #PFMonth

#DYK when someone has #pulmonaryfibrosis (PF), thickened scar tissue builds on the tiny air sacs in their lungs? This can cause shortness of breath & trigger coughing. We aim to change treatment expectations & restore hope for individuals with PF. Get more #PFMonth facts: Pulmonary Fibrosis Foundation

At Endeavor BioMedicines, we are focused on developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. We are evaluating our lead investigational candidate ENV-101 for the treatment of IPF. #PFAM #PFMonth

This #PFMonth & always, Endeavor BioMedicines is inspired by individuals personally impacted by idiopathic pulmonary fibrosis. Learn about our commitment to developing a therapy that precisely targets the root cause of this challenging disease: bit.ly/3MGkZ8Y

Today we had the honor of hosting PF Warriors' Teresa Barnes, Chief Executive Warrior, Dolly Kervitsky, President, and MaryLuz Fuentes, MD, Director, Spanish Language Program, who shared their experience with #pulmonaryfibrosis for #PFMonth. We are inspired by every Pulmonary Fibrosis Warrior!

Endeavor was honored to participate at the International Colloquium on Lung and Airway Fibrosis, #ICLAF2024, where we discussed advancements in #pulmonaryfibrosis. #IPF #innovation

We hope you had a happy #Halloween 🎃! We celebrated with a day filled with creativity, fun, and #innovation.

This #NationalFamilyCaregiversMonth, join us in recognizing and supporting those who care for people with idiopathic #pulmonaryfibrosis (IPF). Thank you for all you do. For great caregiving resources, visit Pulmonary Fibrosis Foundation: bit.ly/3YtTdlx #NFCMonth #familycaregivers

#NEWS: We are pleased to share that the first #patient has been dosed in our Phase 2b WHISTLE-PF #clinicaltrial evaluating our lead #investigational candidate, ENV-101, in patients with #IPF. Learn more here: bit.ly/3UZ19Ku #innovation #meded

We are proud of each person on #TeamEndeavor & thankful for their contributions toward our mission of disrupting disease and restoring hope. As we go into a season of #gratitude, we asked our team what they are grateful for; take a listen to what they said. Happy #Thanksgiving!

Introducing some of our newest team members dedicated to developing transformative medicines. Welcome to #TeamEndeavor! Your expertise will drive us forward as we work to develop therapies that change treatment expectations & restore hope. #NewHires #IPF #Oncology

#NEWS: Endeavor BioMedicines is pleased to welcome Lisa Lancaster, M.D., as Chief Medical Officer. Learn more: bit.ly/4iPQGLc

From fresh air to vibrant communities, our environment shapes the lives we lead and the health we strive for. Today, let's appreciate the world around us—and our shared commitment to healthier futures for all. #EarthDay

#NEWS: Endeavor BioMedicines Announces Upcoming Presentations at #ATS2025. Learn more: bit.ly/4jRQds8 #Biotech #Innovation #MedEd

Today at #ATS2025 we shared new findings from a post hoc analysis of ENV-101 in Phase 2a trial for Idiopathic Pulmonary Fibrosis. Highlights include reductions in pulmonary vessel volume, increase in lung volume, and a trend towards reduced lung fibrosis. bit.ly/4k2ZCNY

June is #MensHealthMonth – a timely reminder that idiopathic pulmonary fibrosis (#IPF), a serious lung disease, is more common in men, especially those over 60. We're dedicated to advancing research and awareness, aiming to improve outcomes for all affected by IPF.

Hard work. Bold science. Endless impact. Texas A&M’s Spirit Magazine spotlights Endeavor BioMedicines CEO Dr. John Hood and his journey from Aggie to biotech trailblazer developing new options to restore hope for patients. Read more: bit.ly/4lmjVpU

Our investigational therapy taladegib (ENV-101) has received Orphan Drug Designation from the European Commission and FDA for idiopathic pulmonary fibrosis. A key milestone in our mission to help deliver new hope for patients. bit.ly/3GHxn9m #IPF #PulmonaryFibrosis

In the post hoc analysis of the ENV-IPF-101 trial presented at #ATS2025, deep-learning AI models detected statistically significant improvements in lung volume and pulmonary vascular volume in #IPF when treated with ENV-101 vs placebo. More: bit.ly/4lHtVuF #meded #medex